Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 3/2012

01.09.2012 | Review Article

Cytokine and endocrine signaling in prostate cancer

verfasst von: J. Puente Vazquez, E. Grande Pulido, L. M. Anton Aparicio

Erschienen in: Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Prostate epithelial and stromal cells develop paracrine interactions, which may be responsible for the occurrence and progression of prostate pathologies. Strikingly, stromal cells exhibit pleiotropic effects on epithelial cell growth, ranging from stimulation to inhibition. Steroid hormone receptors are considered ligand-activated transcriptional factors. Moreover, it has been suggested that the human androgen receptor can also be activated in the absence of surrounding ligands such as growth factors and cytokines. Strong evidence suggests that cytokines may play an important role in ligand-independent activation of androgen receptor in prostate cancer cells. In our view, one of the most striking finding in the prostate cancer development process is the relationship between carcinogenesis and secretion of cytokines.
Literatur
1.
Chang SH, Chung LWK. Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. Endocrinology. 1989;125:2719–27.PubMedCrossRef
2.
Steiner MS. Review of peptide growth factors in bening prostatic hyperplasia and urogenital malignancy. J Urol. 1995;153:1085–6.PubMedCrossRef
3.
4.
Leuprolide Study G. roup:Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311:1281–6.CrossRef
5.
Schellhammer P. Combined androgen blockade for the treatment od metastatic carcinoma od the prostate. Urology. 1996;47:622–8.PubMedCrossRef
6.
McNeal JF. The prostate gland: morphology and pathobiology. Monogr Urol. 1983;4:3–37.
7.
Lipschutz JH, Fukami H, Yamamoto M, Tatematsu M, Sugimura Y, Kusakabe M, Cunha G. Clonality of urogenital organs as determined by analysis of chimeric mice. Cells Tissues Organs. 1999;165(2):57–66.PubMedCrossRef
8.
Takeda H, Nakamoto T, Kokontis J, Chodak GW, Chang C. Autoregulation of androgen receptor expression in rodent prostate: immunohistochemical and in situ hybridization analysis. Biochem Biophys Res Commun. 1991;177(1):488–96.PubMedCrossRef
9.
Cooke PS, Young P, Cuhna GR. Androgen receptor expression in developing male reproductive organs. Endocrinology. 1991;128:2867–73.PubMedCrossRef
10.
Grossman M, Huang H, Tindall D. Androgen receptor signaling in androgen.refractory prostate cancer. J Nat Cancer Inst (Bethesda). 2001;93:1687–97.CrossRef
11.
Talpin NE, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393–8.CrossRef
12.
Gaddipati JP, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994;54:2861–4.PubMed
13.
Visakorpi T, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401–6.PubMedCrossRef
14.
Culing Z, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474–8.
15.
Craft N, Shostak Y, Carey M, Sawyers C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 1999;5:280–5.PubMedCrossRef
16.
Chen T, Wang L, Farrar W. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000;60:2132–5.PubMed
17.
Hobisch A, Eder I, Putz T, Horninger W, Bartsch G, Klocker H, Culing Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998;58:4640–5.PubMed
18.
Marker PC, Donjacour AA, Dahiya R, Cuhna GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol. 2003;253:165–74.PubMedCrossRef
19.
Hayashi N, Cuhna GR, Parker M. Permissive and instructive induction of adult rodent prostatic epithelium by heterotypic urogenital sinus mesenchyme. Epithel Cell Biol. 1993;2:66–78.
20.
Montie JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994;43:892–9.PubMedCrossRef
21.
Brendler CB, Follansbee AL, Isaacs JT. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. J Urol. 1985;133:495–501.PubMed
22.
Hayes RB, de Jong FH, Raatgever J, Bogdanovicz J, Schroeder FH, van der Maas P, Oishi K, Yoshida O. Physical characteristics and factors related to sexual development and behaviour and the risk for prostatic cancer. Eur J Cancer Prev. 1992;1:239–45.PubMedCrossRef
23.
Wang YZ, Hayward SW, Cao M, Young P, Cardiff R, Cuhna GR. Role of estrogen signaling in prostatic hormonal carcinogenesis. J Urol. 2001;165:1320.
24.
Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsal prostate of Noble rats. J Natl Cancer Inst. 1988;80:1045–53.PubMedCrossRef
25.
Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat:the role of insulin-like growth factor-1 (EGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate. 1998;35:165–77.PubMedCrossRef
26.
Wang Y, Sudilovsky B, Zhang B, Haughney PC, Rosen MA, Wu DS, Cuhna TJ, Dahiya R, Cuhna GR, Hayward SW. A Human prostatic epithelial model of hormonal carcinogenesis. Cancer Res. 2001;61:6064–72.PubMed
27.
Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res. 1996;2:215–22.PubMed
28.
Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sghal PB. Interleukin 6 decreases cell–cell association and increases motility of ductal breast carcinoma xcells. J Exp Med. 1989;170:1649–69.PubMedCrossRef
29.
Belizario JE, Dinarello CA. Interleukin a, interleukin 6, tumor necrosis factor, and transforming growth factor β increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. Cancer Res. 1991;51:2379–85.PubMed
30.
Tamm I, Cardinale I, Murphy JS. Decreased adherence on interleukin 6-treated breast carcinoma cells can lead to separation from neigbors after mitosis. Proc Nat Acad Sci (Wash). 1991;88:4414–8.CrossRef
31.
Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. J Immunol. 1993;150:5219–30.PubMed
32.
33.
Hirano T. Interleukin-6. In: Thompson AW, editor. The cytokine handbook. London: Academic Press; 1994. p. 145.
34.
Chen-Kinag S, Hsu W, Natkunam Y, Zhang X. Nuclear signaling by interleukin-6. Curr Opin Immunol. 1993;5:124–8.CrossRef
35.
Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243–54.PubMed
36.
Ihle JM, Kerr IM. Jaks and Stats in signaling by the cytokine reeptor superfamily. Trends Genet. 1995;11:69–74.PubMedCrossRef
37.
Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin6 in porstate carcinoma cells. Cancer Res. 1990;50:7786–8.PubMed
38.
Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol. 1994;151:1396–9.PubMed
39.
Comhaire F, Bosmans E, Ombelet W, Ounjabi U, Schoonjans F. Cytokines in semen of normal men and of patients with andrological diseases. Am J Reprod Immunol. 1994;31:99–103.PubMed
40.
Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak M-P, Millot G, De Cremoux P, Calvo P. Stromal cells from human beningn prostate hyperplasia produce a growtth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer. 1996;69:207–14.CrossRef
41.
Debes JD, Schmidt LJ, Huang H, Tindall DJ. Cancer Res. 2002;62:5632–6.PubMed
42.
Smith PC, Hobisch A, Lin DL, Culing Z, Keller ET. Cytokine Growth Factor Rev. 2001;12:33–40.PubMedCrossRef
43.
44.
Kim O, Jiang T, Xie Y, Guoi Z, Chen H, Qiu Y. Syneregism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2004;23:1838–44.PubMedCrossRef
45.
Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994;151:622–8.PubMed
46.
47.
Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997;159:3113–7.PubMed
48.
Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells of prostate cancer. Clin Cancer Res. 2006;6:2175–82.
49.
Small EJ, Fratesi P, Reese DM, et al. Immunotheapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894–903.PubMed
50.
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.PubMedCrossRef
51.
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–9.PubMedCrossRef
52.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.PubMedCrossRef
53.
Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogenic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol. 2006;24:419–24.PubMedCrossRef
54.
Simons JW, Small E, Nelson W, et al. Phase II trials of a GM-CSF gene-transduced prostate cancer cell line vaccine (GVAX) demonstrated antitumor activity. Proc Am Soc Clin Oncol. 2001;20:1073.
55.
Higano C, Saad F, Somer B et al. (2009) A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Genitourin Cancer Symp (abstract LBA150).
56.
Small E, Demkow T, Gerritsen WR et al. (2009) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Genitourin Cancer Symp (abstract 7).
57.
Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Group. J Clin Oncol. 2004;22:2122–32.PubMedCrossRef
58.
Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099–105.PubMedCrossRef
59.
McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27:425–30.CrossRef
60.
Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer. J Clin Oncol. 2008;26:a5004.CrossRef
Metadaten
Titel
Cytokine and endocrine signaling in prostate cancer
verfasst von
J. Puente Vazquez
E. Grande Pulido
L. M. Anton Aparicio
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0036-4

Weitere Artikel der Ausgabe 3/2012

Medical Oncology 3/2012 Zur Ausgabe

Short Communication

Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML

Original Paper

Urban and non-urban disparities in the use of post-mastectomy radiation for breast cancer

Original Paper

Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia

Original Paper

A novel prognostic model for extranodal natural killer/T-cell lymphoma

Case Report

Extrapulmonary small cell: a novel case of small cell carcinoma of the thyroid gland

Original Paper

The expression of Mcl-1 in human cervical cancer and its clinical significance

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise